OUI A.I CyberSecurity Scoring
01/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Octapharma USA, Inc. in 2026.
No incidents recorded for Octapharma USA, Inc. in 2026.
No incidents recorded for Octapharma USA, Inc. in 2026.
Pharmaceutical Manufacturing
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
Latest updates, reports, and threat intel affecting the global network.
Octapharma Plasma agreed to a $2.55 million class action lawsuit settlement to resolve claims it failed to prevent a 2024 data breach that compromised donor...
OneBlood, a nonprofit organization that provides blood and blood products to health care providers in Florida, Georgia, Alabama,...
The US pharmaceutical company has closed more than 150 plasma collection locations, citing “network issues” – but the truth may be more sinister.
A vulnerability in keras-team/keras version 3.15.0 allows unsafe deserialization of attacker-controlled PyTorch pickle data through the public `keras.layers.TorchModuleWrapper.from_config` method. This method invokes `torch.load(..., weights_only=False)` without requiring an explicit unsafe opt-in, such as a `safe_mode=False` parameter. When called outside a `SafeModeScope(True)` context, the absence of an ambient safe mode state permits unsafe deserialization by default. This issue can lead to arbitrary code execution if untrusted Keras layer configurations are processed using this method. The vulnerability arises because the method does not enforce safe deserialization practices unless explicitly guarded by Keras safe mode.
In the Linux kernel, the following vulnerability has been resolved: iommu/amd: Remove latent out-of-bounds access in IOMMU debugfs In iommu_mmio_write() and iommu_capability_write(), the variables dbg_mmio_offset and dbg_cap_offset are declared as int. However, they are populated using kstrtou32_from_user(). If a user provides a sufficiently large value, it can become a negative integer. Prior to this patch, the AMD IOMMU debugfs implementation was already protected by different mechanisms. 1. #define OFS_IN_SZ 8 ensures the user string <= 8 bytes, so e.g. 0xffffffff isn't a valid input. if (cnt > OFS_IN_SZ) return -EINVAL; 2. Implicit type promotion in iommu_mmio_write(), dbg_mmio_offset is int and iommu->mmio_phys_end is u64 if (dbg_mmio_offset > iommu->mmio_phys_end - sizeof(u64)) return -EINVAL; 3. The show handlers would currently catch the negative number and refuse to perform the read. Replace kstrtou32_from_user() with kstrtos32_from_user() to parse the input, and check for negative values to explicitly prevent out-of-bounds memory accesses directly in iommu_mmio_write() and iommu_capability_write().
In the Linux kernel, the following vulnerability has been resolved: sysfs: don't remove existing directory on update failure When sysfs_update_group() is called for a named group and create_files() fails (e.g. -ENOMEM), internal_create_group() calls kernfs_remove(kn) on the group directory. In the update path, kn was obtained via kernfs_find_and_get() and refers to a directory that already existed before this call. Removing it silently destroys a sysfs group that the caller did not create. Only remove the directory if we created it ourselves. On update failure the directory remains as it is left empty by remove_files() inside create_files(), but can be repopulated by a retry.
In the Linux kernel, the following vulnerability has been resolved: mm/damon/sysfs-schemes: call missing mem_cgroup_iter_break() damon_sysfs_memcg_path_to_id() breaks mem_cgroup_iter() loop without calling mem_cgroup_iter_break(). This leaks the cgroup reference. Fix the issue by calling mem_cgroup_iter_break() before the break. The issue was discovered [1] by Sashiko.
In the Linux kernel, the following vulnerability has been resolved: efi: Allocate runtime workqueue before ACPI init Since commit 5894cf571e14 ("acpi/prmt: Use EFI runtime sandbox to invoke PRM handlers") ACPI PRM calls are delegated to a workqueue which runs in a kernel thread, making it easier to detect and mitigate faulting memory accesses performed by the firmware. Rafael reports that such PRM accesses may occur before efisubsys_init() executes, which is where the workqueue is allocated, leading to NULL pointer dereferences. Since acpi_init() [which triggers the early PRM accesses] executes as a subsys_initcall() as well, and has its own dependencies that may be sensitive to initcall ordering, deferring acpi_init() is not an option. So instead, split off the workqueue allocation into its own postcore initcall, as this is the only missing piece to allow EFI runtime calls to be made. This ensures that EFI runtime call (including PRM calls) are accessible to all code running at subsys_initcall() level.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.